---
title: "Liquid-Liquid Phase Separation (LLPS)"
subtitle: "æ¶²-æ¶²ç›¸åˆ†ç¦» - ç”Ÿç‰©åˆ†å­å‡èšä½“çš„å½¢æˆä¸åŠŸèƒ½"
summary: "LLPSæ˜¯ç»†èƒé€šè¿‡å¤šä»·ç›¸äº’ä½œç”¨ç»„ç»‡ç”ŸåŒ–ååº”çš„æ™®éæœºåˆ¶ï¼Œåœ¨è½¬å½•è°ƒæ§ã€æŸ“è‰²è´¨ç»„ç»‡å’ŒDNAä¿®å¤ä¸­å‘æŒ¥å…³é”®ä½œç”¨"
date: 2025-11-20
authors: ["Yu-Ting Sun"]
tags: ["LLPS", "Phase Separation", "Condensates", "Transcription", "Chromatin", "p53"]
categories: ["Molecular Mechanisms", "Nuclear Biology"]
type: page
toc: true
weight: 3
featured: true

image:
  caption: 'Cellular biomolecular condensates formed by LLPS (Banani et al. 2017)'
  focal_point: "Smart"
  preview_only: false
---

{{< toc >}}

<!-- è¯­è¨€åˆ‡æ¢æŒ‰é’® -->
<div class="lang-toggle">
  <button onclick="toggleLanguage('both')" class="active">ä¸­è‹±å¹¶æ’ Both</button>
  <button onclick="toggleLanguage('zh')">ä»…ä¸­æ–‡ Chinese Only</button>
  <button onclick="toggleLanguage('en')">ä»…è‹±æ–‡ English Only</button>
</div>

<div class="bilingual-section">

<!-- ========== æ¦‚è¿°éƒ¨åˆ† ========== -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

## æ¦‚è¿°

æ¶²-æ¶²ç›¸åˆ†ç¦»ï¼ˆLiquid-Liquid Phase Separation, LLPSï¼‰æ˜¯ç»†èƒå†…ç”Ÿç‰©å¤§åˆ†å­é€šè¿‡**å¤šä»·ç›¸äº’ä½œç”¨**è‡ªå‘å½¢æˆ**æ— è†œç»†èƒå™¨**ï¼ˆmembraneless organellesï¼‰çš„ç‰©ç†åŒ–å­¦è¿‡ç¨‹ã€‚è¿™äº›åŠ¨æ€çš„ç”Ÿç‰©åˆ†å­å‡èšä½“ï¼ˆbiomolecular condensatesï¼‰åœ¨æ—¶ç©ºä¸Šç»„ç»‡ç”ŸåŒ–ååº”ï¼Œå®ç°å¿«é€Ÿã€å¯é€†çš„åŠŸèƒ½è°ƒæ§ã€‚

åœ¨æ ¸ç”Ÿç‰©å­¦ä¸­ï¼ŒLLPSé©±åŠ¨å½¢æˆï¼š
- **è½¬å½•å‡èšä½“**ï¼šæµ“ç¼©è½¬å½•å› å­å’Œå…±æ¿€æ´»å› å­ï¼Œå¢å¼ºåŸºå› æ¿€æ´»
- **å¼‚æŸ“è‰²è´¨åŒºåŸŸ**ï¼šé€šè¿‡HP1Î±ç­‰è›‹ç™½ç›¸åˆ†ç¦»ç»´æŒåŸºå› æ²‰é»˜
- **DNAä¿®å¤ç—…ç¶**ï¼šæ‹›å‹Ÿä¿®å¤è›‹ç™½ï¼ŒåŠ é€ŸæŸä¼¤å“åº”

**ä¸æœ¬é¡¹ç›®çš„å…³è”**ï¼šp53é€šè¿‡å…¶å›ºæœ‰æ— åºåŒºï¼ˆIDRï¼‰é©±åŠ¨ç›¸åˆ†ç¦»ï¼Œå½¢æˆè½¬å½•å‡èšä½“ï¼Œåœ¨ä¸ç»„è›‹ç™½çš„ç«äº‰ä¸­å±€éƒ¨å¢å¼ºæµ“åº¦ï¼Œå…‹æœæ ¸å°ä½“å±éšœã€‚

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

## Overview

Liquid-Liquid Phase Separation (LLPS) is a physicochemical process by which cellular biomacromolecules spontaneously form **membraneless organelles** through **multivalent interactions**. These dynamic biomolecular condensates spatiotemporally organize biochemical reactions, enabling rapid and reversible functional regulation.

In nuclear biology, LLPS drives the formation of:
- **Transcriptional condensates**: Concentrating transcription factors and coactivators to enhance gene activation
- **Heterochromatin domains**: Maintaining gene silencing through phase separation of proteins like HP1Î±
- **DNA repair foci**: Recruiting repair proteins to accelerate damage response

**Connection to this project**: p53 drives phase separation through its intrinsically disordered regions (IDRs), forming transcriptional condensates that locally enhance its concentration to overcome nucleosome barriers in competition with histones.

  </div>
</div>

<!-- ç»†èƒå†…å‡èšä½“å…¨æ™¯å›¾ -->
<div style="text-align: center; margin: 2rem 0;">
  <img src="/images/resource/llps-overview.png" alt="Cellular LLPS-driven condensates" style="max-width: 100%; border-radius: 8px; box-shadow: 0 4px 6px rgba(0,0,0,0.1);">
  <p style="font-size: 0.9rem; color: #64748b; margin-top: 0.5rem;">
    <strong>Figure:</strong> Major LLPS-driven biomolecular condensates in cells<br>
    <em>Source: Banani et al. (2017) Nat Rev Mol Cell Biol 18:285-298</em>
  </p>
</div>

---

<!-- ========== Section 1: LLPSåŸºç¡€æ¦‚å¿µ ========== -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

## Section 1: LLPSåŸºç¡€æ¦‚å¿µ

### 1.1 å®šä¹‰ä¸æ ¸å¿ƒé©±åŠ¨åŠ›

**ä»€ä¹ˆæ˜¯LLPSï¼Ÿ**

LLPSæ˜¯æŒ‡å‡ä¸€æº¶æ¶²åœ¨ç‰¹å®šæ¡ä»¶ä¸‹ï¼ˆæµ“åº¦ã€æ¸©åº¦ã€ç¦»å­å¼ºåº¦ï¼‰åˆ†ç¦»æˆä¸¤ç›¸ï¼š
- **ç¨€ç›¸ï¼ˆdilute phaseï¼‰**ï¼šè›‹ç™½æµ“åº¦ä½ï¼Œç±»ä¼¼ä½“ç›¸
- **è‡´å¯†ç›¸ï¼ˆdense phaseï¼‰**ï¼šè›‹ç™½æµ“åº¦é«˜ï¼Œå½¢æˆæ¶²æ»´çŠ¶å‡èšä½“

**æ ¸å¿ƒé©±åŠ¨åŠ›**ï¼š
1. **å¤šä»·ç›¸äº’ä½œç”¨ï¼ˆMultivalent interactionsï¼‰**
   - å¤šä¸ªå¼±ç›¸äº’ä½œç”¨ä½ç‚¹çš„ååŒæ•ˆåº”
   - é€šè¿‡é™ä½ä½“ç³»è‡ªç”±èƒ½é©±åŠ¨ç›¸åˆ†ç¦» ([Flory-Hugginsç†è®º](https://doi.org/10.1038/nrm.2017.7))

2. **å›ºæœ‰æ— åºåŒºï¼ˆIDRsï¼‰**
   - ç¼ºä¹å›ºå®šä¸‰ç»´ç»“æ„
   - å¯Œå«å¸¦ç”µã€èŠ³é¦™æ—æˆ–ææ€§æ°¨åŸºé…¸
   - æä¾›å¤šä¸ªå¯é€†ç»“åˆä½ç‚¹

3. **ç‰¹å¼‚æ€§ç›¸äº’ä½œç”¨ç±»å‹**ï¼š
   - **Ï€-Ï€å †ç§¯**ï¼šèŠ³é¦™æ—æ®‹åŸºï¼ˆPhe, Tyr, Trpï¼‰
   - **é™ç”µç›¸äº’ä½œç”¨**ï¼šæ­£è´Ÿç”µè·å¸å¼•
   - **ç–æ°´ä½œç”¨**ï¼šç–æ°´æ®‹åŸºèšé›†
   - **æ°¢é”®ç½‘ç»œ**ï¼šææ€§æ®‹åŸºä»‹å¯¼

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

## Section 1: LLPS Fundamentals

### 1.1 Definition and Core Driving Forces

**What is LLPS?**

LLPS refers to the separation of a homogeneous solution into two phases under specific conditions (concentration, temperature, ionic strength):
- **Dilute phase**: Low protein concentration, similar to bulk
- **Dense phase**: High protein concentration, forming droplet-like condensates

**Core Driving Forces**:
1. **Multivalent interactions**
   - Synergistic effects of multiple weak interaction sites
   - Drive phase separation by reducing system free energy ([Flory-Huggins theory](https://doi.org/10.1038/nrm.2017.7))

2. **Intrinsically Disordered Regions (IDRs)**
   - Lack fixed 3D structure
   - Enriched in charged, aromatic, or polar amino acids
   - Provide multiple reversible binding sites

3. **Specific Interaction Types**:
   - **Ï€-Ï€ stacking**: Aromatic residues (Phe, Tyr, Trp)
   - **Electrostatic interactions**: Attraction between opposite charges
   - **Hydrophobic effect**: Clustering of hydrophobic residues
   - **Hydrogen bond networks**: Mediated by polar residues

  </div>
</div>

<!-- 1.2 åˆ†å­åŸºç¡€ -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

### 1.2 åˆ†å­åŸºç¡€

**IDRçš„ç‰¹å¾**ï¼š
- **åºåˆ—ç»„æˆ**ï¼š
  - ä½å¤æ‚åº¦åºåˆ—ï¼ˆLCDï¼‰ï¼šé‡å¤çš„çŸ­æ°¨åŸºé…¸motif
  - Prion-like domainsï¼ˆPrLDsï¼‰ï¼šç±»æœŠç—…æ¯’ç»“æ„åŸŸï¼ˆGln/Asnå¯Œé›†ï¼‰
  - RGG/FGé‡å¤ï¼šRNAç»“åˆè›‹ç™½å¸¸è§

- **ç»“æ„ç‰¹æ€§**ï¼š
  - æ— å›ºå®šäºŒçº§/ä¸‰çº§ç»“æ„
  - æ„è±¡é«˜åº¦çµæ´»ï¼ˆensemble of statesï¼‰
  - å“åº”ç¯å¢ƒå¿«é€Ÿå˜åŒ–

**å…³é”®æ°¨åŸºé…¸ç±»å‹**ï¼š

| ç±»å‹ | ä»£è¡¨æ°¨åŸºé…¸ | ä½œç”¨æœºåˆ¶ |
|------|-----------|---------|
| **èŠ³é¦™æ—** | Phe, Tyr, Trp | Ï€-Ï€å †ç§¯ï¼Œç–æ°´ä½œç”¨ |
| **å¸¦æ­£ç”µ** | Arg, Lys | é™ç”µç›¸äº’ä½œç”¨ï¼Œç»“åˆDNA/RNA |
| **å¸¦è´Ÿç”µ** | Glu, Asp | é™ç”µç›¸äº’ä½œç”¨ï¼Œè°ƒæ§ç›¸åˆ†ç¦»é˜ˆå€¼ |
| **ææ€§** | Ser, Thr, Gln, Asn | æ°¢é”®ç½‘ç»œï¼Œç¨³å®šæ¶²æ»´ |
| **å°åˆ†å­** | Gly, Ala | æä¾›æ„è±¡çµæ´»æ€§ |

**å®ä¾‹**ï¼š
- **p53çš„TADï¼ˆ1-67ï¼‰**ï¼šå¯Œå«Phe/Trpï¼ˆÏ€-Ï€ï¼‰+ é…¸æ€§æ®‹åŸºï¼ˆé™ç”µï¼‰
- **HP1Î±çš„Hinge**ï¼šå¸¦æ­£ç”µIDRï¼Œç»“åˆH3K9me3å¹¶é©±åŠ¨ç›¸åˆ†ç¦»
- **FUSçš„LCD**ï¼šGly/Ser/Gln/Tyrå¯Œé›†ï¼Œå½¢æˆæ°´å‡èƒ¶çŠ¶æ¶²æ»´

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

### 1.2 Molecular Basis

**IDR Characteristics**:
- **Sequence Composition**:
  - Low Complexity Domains (LCDs): Repetitive short amino acid motifs
  - Prion-like Domains (PrLDs): Enriched in Gln/Asn
  - RGG/FG repeats: Common in RNA-binding proteins

- **Structural Properties**:
  - No fixed secondary/tertiary structure
  - Highly flexible conformation (ensemble of states)
  - Rapid response to environmental changes

**Key Amino Acid Types**:

| Type | Representative AAs | Mechanism |
|------|-------------------|-----------|
| **Aromatic** | Phe, Tyr, Trp | Ï€-Ï€ stacking, hydrophobic effect |
| **Positively charged** | Arg, Lys | Electrostatic interactions, DNA/RNA binding |
| **Negatively charged** | Glu, Asp | Electrostatic interactions, regulate phase separation threshold |
| **Polar** | Ser, Thr, Gln, Asn | Hydrogen bond networks, stabilize droplets |
| **Small** | Gly, Ala | Provide conformational flexibility |

**Examples**:
- **p53 TAD (1-67)**: Rich in Phe/Trp (Ï€-Ï€) + acidic residues (electrostatic)
- **HP1Î± Hinge**: Positively charged IDR, binds H3K9me3 and drives phase separation
- **FUS LCD**: Enriched in Gly/Ser/Gln/Tyr, forms hydrogel-like droplets

  </div>
</div>

<!-- 1.3 ç‰©ç†ç‰¹æ€§ -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

### 1.3 å…³é”®ç‰©ç†ç‰¹æ€§

**æµ“åº¦é˜ˆå€¼ï¼ˆSaturation concentration, Csatï¼‰**ï¼š
- è¶…è¿‡æ­¤æµ“åº¦æ—¶å‘ç”Ÿç›¸åˆ†ç¦»
- å—æ¸©åº¦ã€ç›æµ“åº¦ã€pHã€åˆ†å­æ‹¥æŒ¤ç­‰å½±å“
- ç»†èƒé€šè¿‡è°ƒæ§æµ“åº¦æ§åˆ¶å‡èšä½“å½¢æˆ

**åŠ¨æ€æµåŠ¨æ€§**ï¼š
- å‡èšä½“å†…åˆ†å­å¿«é€Ÿäº¤æ¢ï¼ˆç§’-åˆ†é’Ÿçº§ï¼‰
- FRAPå®éªŒï¼šè§å…‰æ¢å¤åŠè¡°æœŸ tâ‚/â‚‚ ~ 10-100 s
- ä¸åŒäºå›ºä½“èšé›†ä½“ï¼ˆå¦‚æ·€ç²‰æ ·è›‹ç™½ï¼‰

**ç¯å¢ƒå› ç´ å½±å“**ï¼š

| å› ç´  | æ•ˆåº” | æœºåˆ¶ |
|------|------|------|
| **æ¸©åº¦â†‘** | ç›¸åˆ†ç¦»å‡å¼± | å¢åŠ ç†µï¼Œç ´åå¼±ç›¸äº’ä½œç”¨ |
| **ç›æµ“åº¦â†‘** | åŒå‘è°ƒèŠ‚ | ä½ç›ä¿ƒè¿›ï¼ˆå±è”½åŒç§ç”µè·ï¼‰ï¼Œé«˜ç›æŠ‘åˆ¶ï¼ˆç«äº‰ç»“åˆï¼‰ |
| **åˆ†å­æ‹¥æŒ¤** | ä¿ƒè¿›ç›¸åˆ†ç¦» | æ’é™¤ä½“ç§¯æ•ˆåº”ï¼Œé™ä½Csat |
| **ç¿»è¯‘åä¿®é¥°** | ç²¾ç»†è°ƒèŠ‚ | ç£·é…¸åŒ–é€šå¸¸æŠ‘åˆ¶ï¼Œç”²åŸºåŒ–/ä¹™é…°åŒ–ä¿ƒè¿› |

**ç›¸å›¾ç¤ºä¾‹**ï¼š

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

### 1.3 Key Physical Properties

**Saturation Concentration (Csat)**:
- Phase separation occurs above this concentration
- Influenced by temperature, salt, pH, molecular crowding
- Cells control condensate formation by regulating concentration

**Dynamic Fluidity**:
- Rapid molecular exchange within condensates (seconds-minutes)
- FRAP experiments: Fluorescence recovery half-time tâ‚/â‚‚ ~ 10-100 s
- Distinct from solid aggregates (e.g., amyloid)

**Environmental Factors**:

| Factor | Effect | Mechanism |
|--------|--------|-----------|
| **Temperatureâ†‘** | Weaken phase separation | Increase entropy, disrupt weak interactions |
| **Saltâ†‘** | Biphasic regulation | Low salt promotes (screen like charges), high salt inhibits (compete for binding) |
| **Molecular crowding** | Promote phase separation | Excluded volume effect, lower Csat |
| **Post-translational modifications** | Fine-tuning | Phosphorylation usually inhibits, methylation/acetylation promote |

**Phase Diagram Example**:

  </div>
</div>

<!-- ç›¸å›¾æ’å›¾ -->
<div style="text-align: center; margin: 2rem 0;">
  <img src="/images/resource/llps-phase-diagram.png" alt="LLPS phase diagram" style="max-width: 80%; border-radius: 8px; box-shadow: 0 4px 6px rgba(0,0,0,0.1);">
  <p style="font-size: 0.9rem; color: #64748b; margin-top: 0.5rem;">
    <strong>Figure:</strong> Phase diagram showing nucleation and spinodal decomposition mechanisms<br>
    <em>Source: Alberti et al. (2019) Cell 176:419-434</em>
  </p>
</div>

<div class="bilingual-pair">
  <div class="lang-zh-block">

**ä¸¤ç§å½¢æˆæœºåˆ¶**ï¼š
- **æˆæ ¸ï¼ˆNucleationï¼‰**ï¼šæµ“åº¦ç•¥è¶…é˜ˆå€¼æ—¶ï¼Œå°æ¶²æ»´é€æ¸é•¿å¤§
- **æ—‹èŠ‚åˆ†è§£ï¼ˆSpinodal decompositionï¼‰**ï¼šæµ“åº¦è¿œè¶…é˜ˆå€¼æ—¶ï¼Œå¿«é€Ÿå½¢æˆç½‘ç»œçŠ¶å‡èšä½“

*è¯¦ç»†ç‰©ç†åŸç†è§ [Alberti et al. 2019](https://doi.org/10.1016/j.cell.2018.12.035)*

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

**Two Formation Mechanisms**:
- **Nucleation**: Small droplets gradually grow when concentration slightly exceeds threshold
- **Spinodal decomposition**: Rapid network formation when concentration far exceeds threshold

*For detailed physical principles, see [Alberti et al. 2019](https://doi.org/10.1016/j.cell.2018.12.035)*

  </div>
</div>

---

<!-- ========== Section 2: LLPSåœ¨æ ¸ç”Ÿç‰©å­¦ä¸­çš„ä½œç”¨ ========== -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

## Section 2: LLPSåœ¨æ ¸ç”Ÿç‰©å­¦ä¸­çš„ä½œç”¨

### 2.1 è½¬å½•è°ƒæ§ä¸­çš„LLPS

#### è½¬å½•å‡èšä½“çš„å½¢æˆ

è½¬å½•æ¿€æ´»éœ€è¦è½¬å½•å› å­ï¼ˆTFsï¼‰ã€å…±æ¿€æ´»å› å­ã€Mediatorå¤åˆä½“å’ŒRNA Pol IIåœ¨ç‰¹å®šåŸºå› ä½ç‚¹çš„ååŒä½œç”¨ã€‚LLPSæä¾›äº†ä¸€ç§**æ—¶ç©ºæµ“ç¼©æœºåˆ¶**ï¼š

**è¶…çº§å¢å¼ºå­ï¼ˆSuper-enhancersï¼‰çš„ç›¸åˆ†ç¦»**ï¼š
- å¤šä¸ªå¢å¼ºå­ç°‡é›†å½¢æˆé«˜æµ“åº¦TFç»“åˆä½ç‚¹
- Mediatorçš„MED1äºšåŸºï¼ˆå«IDRï¼‰é©±åŠ¨ç›¸åˆ†ç¦»
- å½¢æˆè½¬å½•å·¥å‚ï¼ˆtranscription factoriesï¼‰
- æ’é™¤æŠ‘åˆ¶å› å­ï¼Œé€‰æ‹©æ€§å¯Œé›†æ¿€æ´»å› å­

**å…³é”®è½¬å½•å‡èšä½“**ï¼š

| å‡èšä½“ç±»å‹ | æ ¸å¿ƒè›‹ç™½ | é©±åŠ¨åŒºåŸŸ | åŠŸèƒ½ |
|-----------|---------|---------|------|
| **p53å‡èšä½“** â­ | p53 | TAD (1-67) | åº”æ¿€å“åº”ï¼Œç»†èƒå‘¨æœŸé˜»æ» |
| **MYCå‡èšä½“** | MYC, MAX | N-terminal LCD | ç”Ÿé•¿è°ƒæ§ï¼Œä»£è°¢é‡ç¼–ç¨‹ |
| **ERå‡èšä½“** | ER, Mediator | IDR + AF2 | é›Œæ¿€ç´ å“åº” |
| **GCN4å‡èšä½“** | GCN4, Mediator | Acidic AD | è¥å…»ç¼ºä¹å“åº” |

#### p53å‡èšä½“ä¸ç»„è›‹ç™½ç«äº‰ â­â­â­

**p53å¦‚ä½•é€šè¿‡ç›¸åˆ†ç¦»å…‹æœæ ¸å°ä½“å±éšœ**ï¼š

1. **åŸºç¡€çŠ¶æ€**ï¼ˆæ— åº”æ¿€ï¼‰ï¼š
   - p53æµ“åº¦ä½ï¼ˆ~10 nMï¼‰
   - ç»„è›‹ç™½å æ®ä¼˜åŠ¿ï¼ˆ~10 Î¼Mï¼‰
   - æ ¸å°ä½“ç´§å¯†åŒ…è£…DNAï¼Œp53ç»“åˆä½ç‚¹è¢«é®è”½

2. **åº”æ¿€æ¿€æ´»**ï¼ˆDNAæŸä¼¤ï¼‰ï¼š
   - ATM/ATRç£·é…¸åŒ– â†’ p53ç¨³å®šåŒ–
   - p53æµ“åº¦å‰§å¢ï¼ˆ~1 Î¼Mï¼‰
   - **TADé©±åŠ¨ç›¸åˆ†ç¦»å½¢æˆå‡èšä½“**

3. **å±€éƒ¨æµ“åº¦å¢å¼º**ï¼š
   - å‡èšä½“å†…p53æµ“åº¦ï¼š**~100 Î¼M**
   - è¿œè¶…ä½“ç›¸æµ“åº¦ï¼Œæ”¹å˜ç«äº‰å¹³è¡¡
   - åˆ©ç”¨æ ¸å°ä½“å‘¼å¸çª—å£ï¼ˆ50-250 msï¼‰ç»“åˆDNA

4. **æ‹›å‹ŸæŸ“è‰²è´¨é‡å¡‘é…¶**ï¼š
   - p53å‡èšä½“æ‹›å‹Ÿp300/CBPï¼ˆHATæ´»æ€§ï¼‰
   - ç»„è›‹ç™½ä¹™é…°åŒ– â†’ æ ¸å°ä½“ä¸ç¨³å®š
   - SWI/SNFå¤åˆä½“ç§»é™¤æ ¸å°ä½“

5. **ç»´æŒå¼€æ”¾æŸ“è‰²è´¨**ï¼š
   - ç›¸åˆ†ç¦»æŒç»­å­˜åœ¨ï¼ˆåˆ†é’Ÿ-å°æ—¶ï¼‰
   - é˜²æ­¢æ ¸å°ä½“å¿«é€Ÿé‡æ–°ç»„è£…
   - æŒç»­è½¬å½•æ¿€æ´»

**å®éªŒè¯æ®**ï¼š
- Chong et al. (2018): ä½“å¤–é‡æ„p53æ¶²æ»´
- Guo et al. (2019): æ´»ç»†èƒæˆåƒè§‚å¯Ÿp53ç—…ç¶
- çº³ç±³æµä½“å®éªŒï¼ˆè§„åˆ’ä¸­ï¼‰ï¼šæ¨¡æ‹Ÿæ‹¥æŒ¤æ¡ä»¶ä¸‹çš„p53-ç»„è›‹ç™½ç«äº‰

**MYC-p53 Sequential Remodelingå‡è¯´**ï¼š
- å¢æ®–æœŸï¼šMYCå‡èšä½“ä¸»å¯¼ â†’ å¢æ®–åŸºå› æ¿€æ´»
- å¤åˆ¶å‹åŠ›ï¼šR-loopå½¢æˆ â†’ DNAæŸä¼¤
- çŠ¶æ€è½¬æ¢ï¼šMYCå‡èšä½“è§£ä½“ï¼Œp53å‡èšä½“å½¢æˆ
- ä¿®å¤çŠ¶æ€ï¼šp53å‡èšä½“ä¸»å¯¼ â†’ ä¿®å¤åŸºå› æ¿€æ´»

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

## Section 2: LLPS Roles in Nuclear Biology

### 2.1 LLPS in Transcriptional Regulation

#### Formation of Transcriptional Condensates

Transcriptional activation requires cooperative action of transcription factors (TFs), coactivators, Mediator complex, and RNA Pol II at specific gene loci. LLPS provides a **spatiotemporal concentration mechanism**:

**Super-enhancer Phase Separation**:
- Multiple enhancer clusters form high-density TF binding sites
- Mediator's MED1 subunit (containing IDR) drives phase separation
- Form transcription factories
- Exclude repressors, selectively enrich activators

**Key Transcriptional Condensates**:

| Condensate Type | Core Proteins | Driving Region | Function |
|----------------|---------------|----------------|----------|
| **p53 condensate** â­ | p53 | TAD (1-67) | Stress response, cell cycle arrest |
| **MYC condensate** | MYC, MAX | N-terminal LCD | Growth control, metabolic reprogramming |
| **ER condensate** | ER, Mediator | IDR + AF2 | Estrogen response |
| **GCN4 condensate** | GCN4, Mediator | Acidic AD | Nutrient starvation response |

#### p53 Condensates and Histone Competition â­â­â­

**How p53 Overcomes Nucleosome Barriers via Phase Separation**:

1. **Basal State** (No Stress):
   - Low p53 concentration (~10 nM)
   - Histones dominate (~10 Î¼M)
   - Nucleosomes tightly package DNA, p53 binding sites occluded

2. **Stress Activation** (DNA Damage):
   - ATM/ATR phosphorylation â†’ p53 stabilization
   - p53 concentration surges (~1 Î¼M)
   - **TAD-driven phase separation forms condensates**

3. **Local Concentration Enhancement**:
   - p53 concentration inside condensates: **~100 Î¼M**
   - Far exceeds bulk concentration, shifts competitive equilibrium
   - Exploit nucleosome breathing windows (50-250 ms) to bind DNA

4. **Recruit Chromatin Remodelers**:
   - p53 condensates recruit p300/CBP (HAT activity)
   - Histone acetylation â†’ nucleosome destabilization
   - SWI/SNF complex removes nucleosomes

5. **Maintain Open Chromatin**:
   - Phase separation persists (minutes-hours)
   - Prevent rapid nucleosome reassembly
   - Sustain transcriptional activation

**Experimental Evidence**:
- Chong et al. (2018): In vitro reconstitution of p53 droplets
- Guo et al. (2019): Live-cell imaging of p53 foci
- Nanofluidics experiments (planned): Model p53-histone competition under crowding

**MYC-p53 Sequential Remodeling Hypothesis**:
- Proliferation phase: MYC condensate dominates â†’ proliferation gene activation
- Replication stress: R-loop formation â†’ DNA damage
- State transition: MYC condensate dissolves, p53 condensate forms
- Repair state: p53 condensate dominates â†’ repair gene activation

  </div>
</div>

<!-- 2.2 æŸ“è‰²è´¨ç»„ç»‡ -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

### 2.2 æŸ“è‰²è´¨ç»„ç»‡ä¸­çš„LLPS

#### HP1Î±é©±åŠ¨çš„å¼‚æŸ“è‰²è´¨å½¢æˆ

**æœºåˆ¶**ï¼š
1. **è¯†åˆ«**ï¼šHP1Î±çš„Chromodomainè¯†åˆ«H3K9me3
2. **äºŒèšåŒ–**ï¼šHP1Î±åŒæºäºŒèšä½“å½¢æˆ
3. **ç›¸åˆ†ç¦»**ï¼šHingeåŒºï¼ˆIDRï¼‰ä»‹å¯¼å¤šä»·ç›¸äº’ä½œç”¨
4. **æ‰©æ•£**ï¼šHP1Î±æ¶²æ»´æ‹›å‹Ÿæ›´å¤šHP1Î±å’ŒHMTï¼ˆå¦‚SUV39Hï¼‰
5. **æ­£åé¦ˆ**ï¼šæ–°ç”²åŸºåŒ–çš„H3K9me3è¿›ä¸€æ­¥æ‹›å‹ŸHP1Î±

**ç‰¹æ€§**ï¼š
- æ¶²æ»´ç›´å¾„ï¼š0.2-2 Î¼m
- FRAPæ¢å¤æ—¶é—´ï¼š~30 s
- æ’é™¤RNA Pol IIå’Œè½¬å½•æ¿€æ´»å› å­
- ç»´æŒåŸºå› æ²‰é»˜çŠ¶æ€

#### Polycomb bodyå½¢æˆ

**æ ¸å¿ƒæˆåˆ†**ï¼š
- PRC1/PRC2å¤åˆä½“
- CBXè›‹ç™½ï¼ˆè¯†åˆ«H3K27me3ï¼‰
- EZH2ï¼ˆå‚¬åŒ–H3K27me3ï¼‰

**åŠŸèƒ½**ï¼š
- Polycombé¶åŸºå› å…±å®šä½
- å½¢æˆæŠ‘åˆ¶æ€§æ ¸åŒºåŸŸ
- å‘è‚²åŸºå› çš„é•¿ç¨‹æ²‰é»˜

#### å…¶ä»–æ ¸å‡èšä½“

| å‡èšä½“ | æ ¸å¿ƒè›‹ç™½ | åŠŸèƒ½ |
|--------|---------|------|
| **æ ¸ä»** | Nucleolin, Fibrillarin | rRNAè½¬å½•ä¸åŠ å·¥ |
| **æ ¸æ–‘ç‚¹** | SRSF2, SON | mRNAå‰ªæ¥å› å­å‚¨å­˜ |
| **PML body** | PML, SUMO | åº”æ¿€å“åº”ï¼Œè‚¿ç˜¤æŠ‘åˆ¶ |
| **Cajal body** | Coilin | snRNAæˆç†Ÿ |

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

### 2.2 LLPS in Chromatin Organization

#### HP1Î±-Driven Heterochromatin Formation

**Mechanism**:
1. **Recognition**: HP1Î± Chromodomain recognizes H3K9me3
2. **Dimerization**: HP1Î± homodimer formation
3. **Phase Separation**: Hinge region (IDR) mediates multivalent interactions
4. **Spreading**: HP1Î± droplets recruit more HP1Î± and HMTs (e.g., SUV39H)
5. **Positive Feedback**: Newly methylated H3K9me3 further recruits HP1Î±

**Properties**:
- Droplet diameter: 0.2-2 Î¼m
- FRAP recovery time: ~30 s
- Exclude RNA Pol II and transcriptional activators
- Maintain gene silencing state

#### Polycomb Body Formation

**Core Components**:
- PRC1/PRC2 complexes
- CBX proteins (recognize H3K27me3)
- EZH2 (catalyzes H3K27me3)

**Functions**:
- Co-localization of Polycomb target genes
- Form repressive nuclear domains
- Long-range silencing of developmental genes

#### Other Nuclear Condensates

| Condensate | Core Proteins | Function |
|-----------|--------------|----------|
| **Nucleolus** | Nucleolin, Fibrillarin | rRNA transcription & processing |
| **Nuclear speckles** | SRSF2, SON | mRNA splicing factor storage |
| **PML body** | PML, SUMO | Stress response, tumor suppression |
| **Cajal body** | Coilin | snRNA maturation |

  </div>
</div>

<!-- 2.3 DNAæŸä¼¤ä¿®å¤ -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

### 2.3 DNAæŸä¼¤ä¿®å¤ä¸­çš„LLPS

#### ä¿®å¤ç—…ç¶çš„æ¶²æ»´æ€§è´¨

**åŒé“¾æ–­è£‚ï¼ˆDSBï¼‰å“åº”**ï¼š
1. **åˆå§‹ä¿¡å·**ï¼šÎ³H2AXæ ‡è®°æŸä¼¤ä½ç‚¹
2. **53BP1æ‹›å‹Ÿ**ï¼š
   - 53BP1ä½å¤æ‚åº¦åŒºåŸŸé©±åŠ¨ç›¸åˆ†ç¦»
   - å½¢æˆå¾®ç±³çº§ç—…ç¶ï¼ˆä¿®å¤å·¥å‚ï¼‰
   - æµ“ç¼©BRCA1, Rad51ç­‰ä¿®å¤è›‹ç™½

3. **åŠ¨æ€æµåŠ¨æ€§**ï¼š
   - FRAPå®éªŒè¯å®æ¶²æ»´ç‰¹æ€§
   - å…è®¸ä¿®å¤è›‹ç™½å¿«é€Ÿäº¤æ¢
   - æ ¹æ®ä¿®å¤è¿›ç¨‹åŠ¨æ€é‡ç»„

**åŠŸèƒ½ä¼˜åŠ¿**ï¼š
- **æµ“ç¼©æ•ˆåº”**ï¼šæé«˜å±€éƒ¨é…¶æµ“åº¦ï¼ŒåŠ é€Ÿä¿®å¤
- **é€‰æ‹©æ€§åˆ†é…**ï¼šæ’é™¤ä¸ç›¸å…³è›‹ç™½ï¼Œé¿å…å¹²æ‰°
- **å¯é€†æ€§**ï¼šä¿®å¤å®Œæˆåå¿«é€Ÿè§£æ•£

**ç—…ç†æ„ä¹‰**ï¼š
- è¿‡åº¦ç¨³å®šçš„æ¶²æ»´ â†’ ä¿®å¤å»¶è¿Ÿ
- ç›¸åˆ†ç¦»ç¼ºé™· â†’ åŸºå› ç»„ä¸ç¨³å®šæ€§
- é¶å‘æ¶²æ»´åŠ¨æ€ â†’ æ½œåœ¨æ²»ç–—ç­–ç•¥

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

### 2.3 LLPS in DNA Damage Repair

#### Liquid Droplet Properties of Repair Foci

**Double-Strand Break (DSB) Response**:
1. **Initial Signal**: Î³H2AX marks damage site
2. **53BP1 Recruitment**:
   - 53BP1 low-complexity region drives phase separation
   - Forms micrometer-scale foci (repair factories)
   - Concentrates BRCA1, Rad51, and other repair proteins

3. **Dynamic Fluidity**:
   - FRAP experiments confirm droplet properties
   - Allow rapid exchange of repair proteins
   - Dynamically reorganize according to repair progress

**Functional Advantages**:
- **Concentration Effect**: Increase local enzyme concentration, accelerate repair
- **Selective Partitioning**: Exclude irrelevant proteins, avoid interference
- **Reversibility**: Rapidly disassemble after repair completion

**Pathological Significance**:
- Overly stable droplets â†’ repair delay
- Phase separation defects â†’ genomic instability
- Targeting droplet dynamics â†’ potential therapeutic strategies

  </div>
</div>

---

<!-- ========== Section 3: å…³é”®LLPSé©±åŠ¨è›‹ç™½ ========== -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

## Section 3: å…³é”®LLPSé©±åŠ¨è›‹ç™½

ä¸‹è¡¨åˆ—å‡ºäº†ä¸»è¦çš„LLPSé©±åŠ¨è›‹ç™½åŠå…¶ç‰¹å¾ã€‚â­ æ ‡è®°çš„è›‹ç™½ä¸æœ¬é¡¹ç›®ç ”ç©¶é‡ç‚¹ç›¸å…³ã€‚

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

## Section 3: Key LLPS-Driving Proteins

The table lists major LLPS-driving proteins and their characteristics. â­ marks proteins related to project research focus.

  </div>
</div>

<div style="overflow-x: auto; margin: 1.5rem 0;">
<table class="table table-hover table-bordered">
  <thead class="thead-light">
    <tr>
      <th width="12%">Category</th>
      <th width="15%">Protein</th>
      <th width="23%">LLPS-Driving Region</th>
      <th width="30%">Function</th>
      <th width="20%">Details</th>
    </tr>
  </thead>
  <tbody>
    <!-- è½¬å½•å› å­ç±» -->
    <tr style="background: #e0f2fe;">
      <td rowspan="4" style="vertical-align: middle; font-weight: 600; color: #0369a1;">
        <strong>è½¬å½•å› å­<br>Transcription<br>Factors</strong>
      </td>
      <td><strong>p53</strong> â­â­â­</td>
      <td>TAD (aa 1-67)<br><small>Aromatic + Acidic</small></td>
      <td>Stress response, cell cycle arrest, tumor suppression</td>
      <td><a href="/resource/interactions/regulatory/p53/" class="btn btn-sm btn-outline-primary">View â†’</a></td>
    </tr>
    <tr style="background: #e0f2fe;">
      <td><strong>MYC</strong></td>
      <td>N-terminal LCD (aa 1-143)<br><small>Charged residues</small></td>
      <td>Growth control, metabolic regulation</td>
      <td><span class="badge badge-secondary">Planned</span></td>
    </tr>
    <tr style="background: #e0f2fe;">
      <td><strong>NFAT5</strong></td>
      <td>Auxiliary domain<br><small>IDR</small></td>
      <td>Osmotic stress response</td>
      <td>â€”</td>
    </tr>
    <tr style="background: #e0f2fe;">
      <td><strong>GCN4</strong></td>
      <td>Acidic activation domain</td>
      <td>Amino acid starvation response</td>
      <td>â€”</td>
    </tr>
    
    <!-- æŸ“è‰²è´¨è›‹ç™½ç±» -->
    <tr style="background: #d1fae5;">
      <td rowspan="4" style="vertical-align: middle; font-weight: 600; color: #065f46;">
        <strong>æŸ“è‰²è´¨è›‹ç™½<br>Chromatin<br>Proteins</strong>
      </td>
      <td><strong>HP1Î±</strong> â­â­</td>
      <td>Hinge (aa 70-120)<br><small>Positively charged IDR</small></td>
      <td>Heterochromatin formation, gene silencing</td>
      <td><a href="/resource/interactions/structural/hp1/" class="btn btn-sm btn-outline-success">View â†’</a></td>
    </tr>
    <tr style="background: #d1fae5;">
      <td><strong>PRC1 (CBX2)</strong></td>
      <td>C-terminal IDR (aa 300-532)<br><small>Low complexity</small></td>
      <td>Polycomb body formation</td>
      <td>â€”</td>
    </tr>
    <tr style="background: #d1fae5;">
      <td><strong>BRD4</strong></td>
      <td>IDR<br><small>Intrinsically disordered</small></td>
      <td>Super-enhancer assembly, transcription elongation</td>
      <td>â€”</td>
    </tr>
    <tr style="background: #d1fae5;">
      <td><strong>TIP5</strong></td>
      <td>IDR + RNA-binding</td>
      <td>Nucleolar silencing</td>
      <td>â€”</td>
    </tr>
    
    <!-- å…±æ¿€æ´»å› å­ç±» -->
    <tr style="background: #fce7f3;">
      <td rowspan="4" style="vertical-align: middle; font-weight: 600; color: #9f1239;">
        <strong>å…±æ¿€æ´»å› å­<br>Coactivators</strong>
      </td>
      <td><strong>Mediator (MED1)</strong> â­</td>
      <td>IDR (aa 1-580)<br><small>Super-enhancer driver</small></td>
      <td>Transcription factory formation</td>
      <td>â€”</td>
    </tr>
    <tr style="background: #fce7f3;">
      <td><strong>p300/CBP</strong></td>
      <td>CH1-KIX-CH3 linkers<br><small>IDR</small></td>
      <td>Histone acetylation, chromatin opening</td>
      <td>â€”</td>
    </tr>
    <tr style="background: #fce7f3;">
      <td><strong>YAP/TAZ</strong></td>
      <td>C-terminal IDR</td>
      <td>Hippo pathway, mechanotransduction</td>
      <td>â€”</td>
    </tr>
    <tr style="background: #fce7f3;">
      <td><strong>NELF</strong></td>
      <td>RRM + IDR</td>
      <td>Transcription pausing control</td>
      <td>â€”</td>
    </tr>
  </tbody>
</table>
</div>


<!-- IDRå¯¹æ¯”è¡¨æ ¼ -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

### å…³é”®è›‹ç™½çš„IDRç»“æ„ç‰¹å¾

ä¸‹è¡¨æ€»ç»“äº†ä¸»è¦LLPSé©±åŠ¨è›‹ç™½çš„IDRä½ç½®ã€åºåˆ—ç‰¹å¾å’Œé©±åŠ¨æœºåˆ¶ï¼š

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

### IDR Structural Features of Key Proteins

The table summarizes the IDR positions, sequence features, and driving mechanisms of major LLPS-driving proteins:

  </div>
</div>

<div style="overflow-x: auto; margin: 1.5rem 0;">
<table class="table table-hover table-bordered">
  <thead class="thead-light">
    <tr>
      <th>Protein</th>
      <th>IDR Region (aa)</th>
      <th>Key Residues</th>
      <th>Driving Mechanism</th>
      <th>Csat (approx.)</th>
    </tr>
  </thead>
  <tbody>
    <tr style="background: #fef3c7;">
      <td><strong>p53</strong></td>
      <td>TAD (1-67)<br>CTD (363-393)</td>
      <td>Phe, Trp (Ï€-Ï€)<br>Glu, Asp (electrostatic)</td>
      <td>Aromatic stacking + Electrostatic</td>
      <td>~0.5 Î¼M</td>
    </tr>
    <tr>
      <td><strong>MYC</strong></td>
      <td>N-term (1-143)</td>
      <td>Charged residues (Arg, Glu)</td>
      <td>Electrostatic interactions</td>
      <td>~2 Î¼M</td>
    </tr>
    <tr style="background: #d1fae5;">
      <td><strong>HP1Î±</strong></td>
      <td>Hinge (70-120)</td>
      <td>Arg, Lys (positive)<br>RNA-binding</td>
      <td>Electrostatic + RNA bridging</td>
      <td>~1 Î¼M</td>
    </tr>
    <tr>
      <td><strong>CBX2</strong></td>
      <td>C-term (300-532)</td>
      <td>Low complexity</td>
      <td>Weak multivalent interactions</td>
      <td>~5 Î¼M</td>
    </tr>
    <tr style="background: #fce7f3;">
      <td><strong>MED1</strong></td>
      <td>IDR (1-580)</td>
      <td>Ser, Thr, Gln-rich</td>
      <td>Polar interactions + TF binding</td>
      <td>~0.1 Î¼M</td>
    </tr>
    <tr>
      <td><strong>FUS</strong></td>
      <td>LCD (1-267)</td>
      <td>Gly, Ser, Gln, Tyr</td>
      <td>Ï€-Ï€ + Hydrogen bonds</td>
      <td>~0.05 Î¼M</td>
    </tr>
  </tbody>
</table>
</div>

<div class="bilingual-pair">
  <div class="lang-zh-block">

**è¡¨æ ¼è¯´æ˜**ï¼š
- **Csat**ï¼šä½“å¤–æµ‹å®šçš„ç›¸åˆ†ç¦»æµ“åº¦é˜ˆå€¼ï¼ˆå®é™…ç»†èƒå†…å—å¤šç§å› ç´ è°ƒæ§ï¼‰
- **é«˜äº®è¡Œ**ï¼šä¸æœ¬é¡¹ç›®ç ”ç©¶é‡ç‚¹ç›¸å…³ï¼ˆp53, HP1Î±, MED1ï¼‰
- **FUS**ï¼šRNAç»“åˆè›‹ç™½ï¼Œä½œä¸ºç»å…¸LLPSæ¨¡å‹è›‹ç™½åˆ—å‡º

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

**Table Notes**:
- **Csat**: In vitro measured phase separation concentration threshold (regulated by multiple factors in cells)
- **Highlighted rows**: Related to project research focus (p53, HP1Î±, MED1)
- **FUS**: RNA-binding protein, listed as a classical LLPS model protein

  </div>
</div>

---

<!-- ========== æ¨èé˜…è¯»åŒº ========== -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

## æ¨èé˜…è¯» | Recommended Reading

### é‡Œç¨‹ç¢‘ç»¼è¿°

1. **Banani SF, Lee HO, Hyman AA, Rosen MK (2017)**
   *Biomolecular condensates: organizers of cellular biochemistry*
   **Nat Rev Mol Cell Biol** 18:285-298
   [DOI: 10.1038/nrm.2017.7](https://doi.org/10.1038/nrm.2017.7)
   - LLPSé¢†åŸŸçš„å…¨é¢ç»¼è¿°ï¼Œæ¶µç›–åŸºæœ¬åŸç†ã€ç”Ÿç‰©å­¦åŠŸèƒ½å’Œç–¾ç—…ç›¸å…³æ€§

2. **Sabari BR, Dall'Agnese A, Young RA (2020)**
   *Biomolecular condensates in the nucleus*
   **Trends Biochem Sci** 45:961-977
   [DOI: 10.1016/j.tibs.2020.06.007](https://doi.org/10.1016/j.tibs.2020.06.007)
   - èšç„¦è½¬å½•å‡èšä½“çš„å½¢æˆã€åŠŸèƒ½å’Œè°ƒæ§æœºåˆ¶

### p53ç›¸å…³åŸåˆ›ç ”ç©¶

3. **Chong S, Dugast-Darzacq C, Liu Z, et al. (2018)**
   *Imaging dynamic and selective low-complexity domain interactions that control gene transcription*
   **Science** 361:eaar2555
   [DOI: 10.1126/science.aar2555](https://doi.org/10.1126/science.aar2555)
   - é¦–æ¬¡åœ¨æ´»ç»†èƒä¸­è§‚å¯Ÿåˆ°p53ç­‰è½¬å½•å› å­çš„æ¶²æ»´åŠ¨æ€

4. **Guo YE, Manteiga JC, Henninger JE, et al. (2019)**
   *Pol II phosphorylation regulates a switch between transcriptional and splicing condensates*
   **Nature** 572:543-548
   [DOI: 10.1038/s41586-019-1464-0](https://doi.org/10.1038/s41586-019-1464-0)
   - æ­ç¤ºè½¬å½•å‡èšä½“ä¸å‰ªæ¥å‡èšä½“çš„åŠ¨æ€è½¬æ¢

### å¼‚æŸ“è‰²è´¨ç›¸åˆ†ç¦»

5. **Strom AR, Emelyanov AV, Mir M, et al. (2017)**
   *Phase separation drives heterochromatin domain formation*
   **Nature** 547:241-245
   [DOI: 10.1038/nature22989](https://doi.org/10.1038/nature22989)
   - è¯æ˜HP1Î±é€šè¿‡ç›¸åˆ†ç¦»é©±åŠ¨å¼‚æŸ“è‰²è´¨å½¢æˆ

6. **Sanulli S, Trnka MJ, Dharmarajan V, et al. (2019)**
   *HP1 reshapes nucleosome-containing chromatin*
   **Nature** 575:390-394
   [DOI: 10.1038/s41586-019-1669-2](https://doi.org/10.1038/s41586-019-1669-2)
   - Fierzå®éªŒå®¤æ­ç¤ºHP1Î±å¦‚ä½•é€šè¿‡ç›¸åˆ†ç¦»é‡å¡‘æŸ“è‰²è´¨ç»“æ„

### ç‰©ç†æœºåˆ¶ä¸ç†è®º

7. **Alberti S, Gladfelter A, Mittag T (2019)**
   *Considerations and challenges in studying liquid-liquid phase separation and biomolecular condensates*
   **Cell** 176:419-434
   [DOI: 10.1016/j.cell.2018.12.035](https://doi.org/10.1016/j.cell.2018.12.035)
   - è®¨è®ºLLPSç ”ç©¶çš„æ–¹æ³•å­¦æŒ‘æˆ˜å’Œæ³¨æ„äº‹é¡¹

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

## Recommended Reading

### Milestone Reviews

1. **Banani SF, Lee HO, Hyman AA, Rosen MK (2017)**
   *Biomolecular condensates: organizers of cellular biochemistry*
   **Nat Rev Mol Cell Biol** 18:285-298
   [DOI: 10.1038/nrm.2017.7](https://doi.org/10.1038/nrm.2017.7)
   - Comprehensive review of LLPS, covering principles, biological functions, and disease relevance

2. **Sabari BR, Dall'Agnese A, Young RA (2020)**
   *Biomolecular condensates in the nucleus*
   **Trends Biochem Sci** 45:961-977
   [DOI: 10.1016/j.tibs.2020.06.007](https://doi.org/10.1016/j.tibs.2020.06.007)
   - Focus on transcriptional condensate formation, function, and regulation

### p53-Related Original Research

3. **Chong S, Dugast-Darzacq C, Liu Z, et al. (2018)**
   *Imaging dynamic and selective low-complexity domain interactions that control gene transcription*
   **Science** 361:eaar2555
   [DOI: 10.1126/science.aar2555](https://doi.org/10.1126/science.aar2555)
   - First observation of p53 and other TF droplet dynamics in live cells

4. **Guo YE, Manteiga JC, Henninger JE, et al. (2019)**
   *Pol II phosphorylation regulates a switch between transcriptional and splicing condensates*
   **Nature** 572:543-548
   [DOI: 10.1038/s41586-019-1464-0](https://doi.org/10.1038/s41586-019-1464-0)
   - Reveals dynamic transition between transcriptional and splicing condensates

### Heterochromatin Phase Separation

5. **Strom AR, Emelyanov AV, Mir M, et al. (2017)**
   *Phase separation drives heterochromatin domain formation*
   **Nature** 547:241-245
   [DOI: 10.1038/nature22989](https://doi.org/10.1038/nature22989)
   - Demonstrates HP1Î±-driven heterochromatin formation via phase separation

6. **Sanulli S, Trnka MJ, Dharmarajan V, et al. (2019)**
   *HP1 reshapes nucleosome-containing chromatin*
   **Nature** 575:390-394
   [DOI: 10.1038/s41586-019-1669-2](https://doi.org/10.1038/s41586-019-1669-2)
   - Fierz lab reveals how HP1Î± reshapes chromatin structure via phase separation

### Physical Mechanisms and Theory

7. **Alberti S, Gladfelter A, Mittag T (2019)**
   *Considerations and challenges in studying liquid-liquid phase separation and biomolecular condensates*
   **Cell** 176:419-434
   [DOI: 10.1016/j.cell.2018.12.035](https://doi.org/10.1016/j.cell.2018.12.035)
   - Discusses methodological challenges and considerations in LLPS research

  </div>
</div>

---

<!-- çŠ¶æ€è¯´æ˜ -->
<div class="bilingual-pair">
  <div class="lang-zh-block">

<div class="alert alert-success">
  <strong>âœ… æœ¬é¡µé¢çŠ¶æ€ï¼š</strong>åŒè¯­å®Œæ•´ç‰ˆ | LLPS mechanism resource | å®Œæ•´å†…å®¹ | Last updated: 2025-11-20
</div>

<div class="alert alert-info">
  <strong>ğŸ”— äº¤å‰å¼•ç”¨ï¼š</strong>æœ¬æœºåˆ¶æ¶‰åŠçš„è›‹ç™½è¯¦è§ 
  <a href="/resource/interactions/structural/">Structural Proteins</a>ã€
  <a href="/resource/interactions/regulatory/">Regulatory Proteins</a>
</div>

<div class="alert alert-warning">
  <strong>ğŸ”¬ ç ”ç©¶äº®ç‚¹ï¼š</strong>æœ¬é¡µé¢ç‰¹åˆ«å¼ºè°ƒäº†p53é€šè¿‡ç›¸åˆ†ç¦»å…‹æœæ ¸å°ä½“å±éšœçš„æœºåˆ¶ï¼Œæ”¯æ’‘"p53-ç»„è›‹ç™½ç«äº‰"ç ”ç©¶æ„¿æ™¯ã€‚MYC-p53 sequential remodelingå‡è¯´ä¸ºæœªæ¥ç ”ç©¶æ–¹å‘ã€‚
</div>

  </div>

  <div class="bilingual-divider"></div>

  <div class="lang-en-block">

<div class="alert alert-success">
  <strong>âœ… Page Status:</strong>Bilingual Complete Version | LLPS mechanism resource | Full Content | Last updated: 2025-11-20
</div>

<div class="alert alert-info">
  <strong>ğŸ”— Cross-references:</strong>Proteins involved in this mechanism can be found in 
  <a href="/resource/interactions/structural/">Structural Proteins</a>, 
  <a href="/resource/interactions/regulatory/">Regulatory Proteins</a>
</div>

<div class="alert alert-warning">
  <strong>ğŸ”¬ Research Highlights:</strong>This page emphasizes the mechanism by which p53 overcomes nucleosome barriers through phase separation, supporting the "p53-histone competition" research vision. The MYC-p53 sequential remodeling hypothesis represents a future research direction.
</div>

  </div>
</div>

</div>

<!-- JavaScript for language toggle -->
<script>
function toggleLanguage(lang) {
  const section = document.querySelector('.bilingual-section');
  const buttons = document.querySelectorAll('.lang-toggle button');
  
  buttons.forEach(btn => btn.classList.remove('active'));
  
  if (lang === 'zh') {
    section.classList.add('hide-en');
    section.classList.remove('hide-zh');
    buttons[1].classList.add('active');
  } else if (lang === 'en') {
    section.classList.add('hide-zh');
    section.classList.remove('hide-en');
    buttons[2].classList.add('active');
  } else {
    section.classList.remove('hide-zh', 'hide-en');
    buttons[0].classList.add('active');
  }
}
</script>

<style>
/* Card hover effect */
.hover-card {
  transition: transform 0.3s ease, box-shadow 0.3s ease;
}

.hover-card:hover {
  transform: translateY(-5px);
  box-shadow: 0 8px 16px rgba(0,0,0,0.15) !important;
}

/* Protein card styling - Fix overlapping issue */
.protein-item {
  display: block;
  padding: 0.75rem 0;
  border-bottom: 1px solid #f1f5f9;
  min-height: 80px;
}

.protein-item:last-child {
  border-bottom: none;
}

.protein-name {
  display: block;
  margin-bottom: 0.5rem;
  line-height: 1.4;
}

.protein-details {
  display: block;
  margin-bottom: 0.5rem;
}

.protein-details small {
  display: block;
  margin-bottom: 0.25rem;
  line-height: 1.5;
}

.priority-badge {
  display: inline-block;
  margin-left: 0.25rem;
  font-size: 0.9em;
  vertical-align: middle;
}

/* Ensure proper alignment in bilingual blocks */
.lang-zh-block h3, .lang-en-block h3 {
  color: #1e293b;
  border-bottom: 2px solid #e5e7eb;
  padding-bottom: 0.5rem;
  margin-bottom: 1rem;
}

.lang-zh-block h4, .lang-en-block h4 {
  color: #475569;
  margin-top: 1.5rem;
}

/* Table styling enhancement */
.table-hover tbody tr:hover {
  background-color: #f0f9ff;
}

/* Dark mode support */
@media (prefers-color-scheme: dark) {
  .protein-item {
    border-bottom-color: #334155;
  }
  
  .lang-zh-block h3, .lang-en-block h3 {
    color: #e2e8f0;
    border-bottom-color: #475569;
  }
  
  .lang-zh-block h4, .lang-en-block h4 {
    color: #cbd5e1;
  }
  
  .table-hover tbody tr:hover {
    background-color: #1e3a5f;
  }
  
  .card {
    background: #1e293b;
    border-color: #334155;
  }
  
  .alert-success {
    background-color: #064e3b;
    border-color: #065f46;
    color: #d1fae5;
  }
  
  .alert-info {
    background-color: #1e3a8a;
    border-color: #1e40af;
    color: #dbeafe;
  }
  
  .alert-warning {
    background-color: #78350f;
    border-color: #92400e;
    color: #fef3c7;
  }
}
</style>
